Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 196.75M P/E - EPS this Y 51.10% Ern Qtrly Grth -
Income -164.66M Forward P/E -4.33 EPS next Y 52.20% 50D Avg Chg 11.00%
Sales 136.3M PEG 0.51 EPS past 5Y - 200D Avg Chg 38.00%
Dividend N/A Price/Book N/A EPS next 5Y -8.06% 52W High Chg -5.00%
Recommedations 1.70 Quick Ratio 3.45 Shares Outstanding 371.15M 52W Low Chg 173.00%
Insider Own 1.95% ROA -13.28% Shares Float 48.55M Beta 1.58
Inst Own 72.12% ROE -33.51% Shares Shorted/Prior 22.25M/21.80M Price 2.51
Gross Margin 30.14% Profit Margin -87.05% Avg. Volume 282,504 Target Price 3.17
Oper. Margin -29.42% Earnings Date Nov 5 Volume 125,606 Change 0.00%
About Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Standard BioTools Inc. News
11/07/24 Standard BioTools Appoints Alex Kim as Chief Financial Officer
11/02/24 Earnings Release: Here's Why Analysts Cut Their Standard BioTools Inc. (NASDAQ:LAB) Price Target To US$3.17
11/01/24 Standard BioTools Third Quarter 2024 Earnings: Beats Expectations
10/31/24 Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ...
10/31/24 Standard BioTools to Participate in Upcoming Investor Conferences
10/30/24 Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates
10/30/24 Standard BioTools: Q3 Earnings Snapshot
10/30/24 Standard BioTools Reports Third Quarter 2024 Financial Results
08:03 PM Millennium Management LLC Acquires Shares in Standard BioTools Inc
10/16/24 Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024
10/03/24 Is Standard BioTools Inc. (LAB) the Best NASDAQ Stock Under $5?
09/24/24 Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform
09/19/24 Shareholders in Standard BioTools (NASDAQ:LAB) are in the red if they invested three years ago
09/18/24 Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH)
08/26/24 Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
08/09/24 Standard BioTools Second Quarter 2024 Earnings: Misses Expectations
08/01/24 Q2 2024 Standard BioTools Inc Earnings Call
07/31/24 Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates
07/31/24 Standard BioTools: Q2 Earnings Snapshot
07/31/24 Standard BioTools Announces Senior Leadership Changes
LAB Chatroom

User Image lejomo Posted - 3 hours ago

@The_Joker_has_Spoken If you're a subscriber member, it will be bullish $LAB. Otherwise, it's bearish . I am just guessing GLTA

User Image goofyfoot Posted - 3 days ago

$LAB

User Image Estimize Posted - 1 week ago

Wall St is expecting -0.06 EPS for $LAB Q4 [Reporting 02/12 AMC] http://www.estimize.com/intro/lab?chart=historical&metric_name=eps&utm_con

User Image rangerhawkeye Posted - 1 week ago

$LAB give me 1.70 again please

User Image Rebooter Posted - 1 week ago

$QSI ARK did not sell QSI today, but did sell another 300K shares of $LAB (formerly SomaLogic). ARK appears to be sticking by their five-year thesis for QSI.

User Image GreenPond Posted - 2 weeks ago

$LAB The previous CFO, Jeffrey Black, "paid US$2.25 per share to buy US$194k worth of the stock" out of own pocket. Will the new CFO? https://finance.yahoo.com/news/jeffrey-black-spends-us-194k-100511294.html

User Image GreenPond Posted - 2 weeks ago

$LAB With the cost reduction realized, I wonder whether they can come up with optimal pricing strategies for the instruments. At old times, this was the key for John D. Rockefeller to gain competitive advantage and win over their competitors. Another thing is they probably should also increase their efforts to promote the instruments to Governments, like NIH, HHS etc.

User Image LittleIronman2 Posted - 2 weeks ago

$SYRS doubled position here today. Also added a tiny bit more $lab but will be waiting to slap on the reversal

User Image GreenPond Posted - 10/31/24

$LAB “On November 7, Illumina will present updates on its proteomics solution, Illumina Protein Prep, which delivers sample-to-analysis protein discovery. The solution is an outcome of Illumina's partnership with Standard BioTools (formerly SomaLogic), announced in 2022.” ... “When it launches in early 2025, Illumina Protein Prep will feature 9000 unique human proteins.” https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=a8203e6f-0b9a-4aa6-9f5e-8037fc464e39

User Image GreenPond Posted - 10/31/24

$LAB If you know how John D. Rockefeller succeeded, you should know how important the cost control/reduction is. Well done, Standard Biotools management! Next step, lets see how you use the cash at hand to generate fresh revenue inflow.

User Image Jkpga Posted - 10/31/24

$LAB 😖

User Image _www_larval_com_ Posted - 10/31/24

$LAB has reversed -3% lower to 9% (~3Mv) moments ago, 11/15 options, follow for more volatility.

User Image Jkpga Posted - 10/31/24

$LAB 😳🔥

User Image goofyfoot Posted - 10/31/24

$LAB I certainly called this one wrong. I chickened out on Tuesday for a small profit thinking the ER would be bad. Damnit!

User Image NoRisksNoFun Posted - 10/31/24

$LAB cathy sold out again!

User Image rangerhawkeye Posted - 10/31/24

$LAB

User Image beckphan08 Posted - 10/31/24

$LAB LETS GOOOOO

User Image VrtcIl Posted - 10/31/24

Do not chase $LAB and wait for consolidations to enter with defined risk. Monitoring the chart during consolidation phases can offer more controlled and calculated trades. Price: 2.19 Float: 77.4M Short Float: 5.9 % 💰 Dollar Volume: 73.1K ℹ️ USA | Diagnostics & Research

User Image Skyshores Posted - 10/31/24

$LAB

User Image Rebooter Posted - 10/30/24

$QSI 1.1 million shares of $LAB (Standard Biotools) sold by $ARKG today.

User Image Profitrip Posted - 10/30/24

$LAB 3Q revenue $45M / push

User Image WHO905 Posted - 10/30/24

$LAB Fundamentals are improving which is a good thing but this was the most lackluster presentation I've listened to in years. In addition there is no context on market size and share of their product lines. It's like the only thing to tout is operational efficiency, or losing less money per quarter than before.

User Image Profitrip Posted - 10/30/24

$LAB Q3 beats / guidance good

User Image HFlier Posted - 10/30/24

$LAB Beat on top and bottom lines.

User Image Rebooter Posted - 10/29/24

$QSI Looks like ARK is dumping their position in Standard Biotools ($LAB). They sold 615K shares today. LAB is the company that merged with SomaLogic earlier this year. That leaves QSI as the only pure play proteomics name in the ARK portfolio, after they dumped Nautilus a couple years ago. ARK owns 12% of QSI and is the second largest shareholder behind founder Jonathon Rothberg. Presumably with a position of that size, they are receiving periodic business updates from QSI management. Interesting to see that ARK is selling LAB two weeks before QSI reports earnings and provides guidance for 2025.

User Image Estimize Posted - 10/28/24

Wall St is expecting -0.09 EPS for $LAB Q3 [Reporting 10/30 AMC] http://www.estimize.com/intro/lab?chart=historical&metric_name=eps&utm_con

User Image Jkpga Posted - 10/25/24

$LAB think this is going much lower 🤷🏼‍♂️

User Image goofyfoot Posted - 10/25/24

$LAB Added more at $1.68.

User Image rangerhawkeye Posted - 10/25/24

$LAB added for a swing 1.71

User Image Geegaa Posted - 10/24/24

$LAB Adding more here.. Blackrock entered.. RUN baby now..like another $DRUG

Analyst Ratings
TD Cowen Buy Aug 1, 24
TD Cowen Buy Apr 16, 24
Jefferies Buy Apr 4, 24
Keybanc Overweight Jul 12, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Black Jeffrey G. SVP & Chief Financia.. SVP & Chief Financial Officer May 18 Buy 2.25 85,984 193,464 85,984 05/22/23
Casdin Eli Director Director May 17 Buy 2.11 1,200,000 2,532,000 1,200,000 05/19/23
Casdin Partners Master Fund, L... Director Director May 17 Buy 2.11 1,200,000 2,532,000 1,200,000 05/19/23
Caligan Partners LP 10% Owner 10% Owner Aug 03 Buy 1.75 301,182 527,068 11,444,836 08/05/22
Caligan Partners LP 10% Owner 10% Owner Jul 29 Buy 1.51 620,466 936,904 11,143,654 08/02/22
Caligan Partners LP - - Jun 13 Buy 1.70 100,000 170,000 10,523,188 06/15/22
Caligan Partners LP 10% Owner 10% Owner Jun 02 Buy 1.95 450,000 877,500 10,423,188 06/06/22
Caligan Partners LP 10% Owner 10% Owner May 06 Buy 2.71 488,350 1,323,428 9,973,188 05/10/22
Caligan Partners LP 10% Owner 10% Owner Apr 28 Buy 2.62 400,000 1,048,000 9,484,838 05/02/22
Caligan Partners LP 10% Owner 10% Owner Apr 06 Buy 3.75 509,573 1,910,899 8,889,838 04/08/22
BARTHELEMY NICOLAS Director Director Mar 31 Option 3.43 5,000 17,150 183,084 04/01/22
Linthwaite Stephen Christopher President & CEO President & CEO Nov 24 Option 0 19,445 239,958 11/24/20
Linthwaite Stephen Christopher President & CEO President & CEO Nov 24 Sell 6.06 84,820 514,009 145,347 11/24/20